Hoffmann-la Roche Inc.

Dietrich Stuber

Heinz Dobeli

Werner Lesslauer

Reiner Gentz

Hansruedi Lotscher

Erich Hochuli

Bernhard Eggimann

David Banner

Peter Jakob

Gerda Huber Trottman

Nicholas Draeger

Methods are disclosed for the production and purification of hydrophobic fusion proteins production and purification of said hydrophobic polypeptides, proteins or peptides. Homogeneous monomeric .beta.-amyloid peptide and tests for screening amyloid toxicity-inhibiting drugs using this monomeric .beta.-amyloid peptide relate to these fusion proteins.

Process for producing hydrophobic polypeptides and proteins, and fusion

Human TNF muteins having higher binding affinity for human p75-TNF receptor than for human p55-TNF receptor include muteins having at least one different amino acid relative to wild-type human TNF at a position corresponding to position 33, 65, 67, 75, 87, 143, 145 or 147 of the wild-type amino acid sequence.

Tumor necrosis factor muteins

The present invention is directed to a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof having selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor characterized in that the amino acid sequence of human Tumor Necrosis Factor is changed at least at position 86 having a threonine instead of a serine residue, a DNA sequence coding for such a mutein, a vector comprising such a DNA sequence, and a host cell transformed by such a vector.

TNF-muteins

Fusion proteins and a process for their purification by means of metal chelate affinity chromatography on NTA resins are provided by this invention.

Affinity peptides

Growing community of inventors

Grenzach-Wyhlen, Germany

Dietrich Stuber